Ono And Astellas Obtain Approval For Osteoporosis Drug
This article was originally published in PharmAsia News
Executive Summary
Osaka based Ono Pharmaceutical and Tokyo based Astellas announced Jan. 21 that osteoporosis drug RECALBON/Bonoteo (minodronic acid) obtained manufacturing and marketing approval from Japan's Ministry of Health, Labor and Welfare on the same date. Jointly developed by the two companies, the new drug application was filed in July 2006. ( href='http://www.jiji.com/jc/c?g=ind_30&k=2009012100641'>Click here for more Japanese language
You may also be interested in...
Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time
Small sterilizers told Medtech Insight that they were ready for the EPA’s controversial EtO emissions rule, while community advocates expressed concerns.
Day One Springs Into Commercial Action With Ojemda Approval
The company is targeting around 200 centers that treat the vast majority of the few thousand pediatric low-grade glioma patients who are candidates for the RAF-targeting drug.
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.